Europe Biopharmaceuticals Market to 2028 - By Size, Share, Growth by End User and Forecast

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Europe Biopharmaceuticals Market – by Product Type

1.3.2 Europe Biopharmaceuticals Market – by Application

1.3.3 Europe Biopharmaceuticals Market – by Country

2. Europe Biopharmaceuticals Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Biopharmaceuticals Market – Market Landscape

4.1 Overview

4.2 Europe PEST Analysis

4.3 Expert’s Opinion

5. Europe Biopharmaceuticals Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Application in Cancer Therapeutics

5.1.2 Potential to Treat Rare Diseases

5.2 Market Restraints

5.2.1 High Cost of Manufacturing Infrastructure

5.3 Market Opportunities

5.3.1 Accelerated Clinical Trials

5.4 Future Trends

5.4.1 Contract Manufacturing of Biopharmaceuticals

5.5 Impact Analysis

6. Biopharmaceuticals Market – Europe Analysis

6.1 Europe Biopharmaceuticals Market Revenue Forecast and Analysis

7. Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 – by Product Type

7.1 Overview

7.2 Europe Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)

7.3 Monoclonal Antibodies

7.3.1 Overview

7.3.2 Monoclonal Antibodies: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Recombinant Vaccines

7.4.1 Overview

7.4.2 Recombinant Vaccines: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.1 Cancer Vaccine

7.4.2.1.1 Overview

7.4.2.1.2 Cancer Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.2 Malaria Vaccine

7.4.2.2.1 Overview

7.4.2.2.2 Malaria Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.3 Ebola Vaccine

7.4.2.3.1 Overview

7.4.2.3.2 Ebola Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.4 Hepatitis-B Vaccine

7.4.2.4.1 Overview

7.4.2.4.2 Hepatitis-B Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.5 Tetanus Vaccine

7.4.2.5.1 Overview

7.4.2.5.2 Tetanus Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.6 Diphtheria Vaccine

7.4.2.6.1 Overview

7.4.2.6.2 Diphtheria Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.7 Cholera Vaccine

7.4.2.7.1 Overview

7.4.2.7.2 Cholera Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.4.2.8 Others

7.4.2.8.1 Overview

7.4.2.8.2 Others: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.5 Conventional Vaccines

7.5.1 Overview

7.5.2 Conventional Vaccines: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.5.2.1 Polio Vaccine

7.5.2.1.1 Overview

7.5.2.1.2 Polio Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.5.2.2 Pox Vaccine

7.5.2.2.1 Overview

7.5.2.2.2 Pox Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.5.2.3 Other Conventional Vaccine

7.5.2.3.1 Overview

7.5.2.3.2 Other Conventional Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.6 Recombinant Growth Factors

7.6.1 Overview

7.6.2 Recombinant Growth Factors: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.6.2.1 Erythropoietin

7.6.2.1.1 Overview

7.6.2.1.2 Erythropoietin: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.6.2.2 Granulocyte Colony Stimulating Factor

7.6.2.2.1 Overview

7.6.2.2.2 Granulocyte Colony Stimulating Factor: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.7 Purified Proteins

7.7.1 Overview

7.7.2 Purified Proteins: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.7.2.1 Leukemia Inhibitory Factor (LIF)

7.7.2.1.1 Overview

7.7.2.1.2 Leukemia Inhibitory Factor (LIF): Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.7.2.2 P53 Protein

7.7.2.2.1 Overview

7.7.2.2.2 P53 Protein: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.7.2.3 P38 Protein

7.7.2.3.1 Overview

7.7.2.3.2 P38 Protein: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.7.2.4 Other Purified Proteins

7.7.2.4.1 Overview

7.7.2.4.2 Other Purified Proteins: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.8 Recombinant Proteins

7.8.1 Overview

7.8.2 Recombinant Proteins: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.8.2.1 Serum Albumin

7.8.2.1.1 Overview

7.8.2.1.2 Serum Albumin: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.8.2.2 Amyloid Protein

7.8.2.2.1 Overview

7.8.2.2.2 Amyloid Protein: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.8.2.3 Defensin

7.8.2.3.1 Overview

7.8.2.3.2 Defensin: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.8.2.4 Transferrin

7.8.2.4.1 Overview

7.8.2.4.2 Transferrin: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.9 Recombinant Hormones

7.9.1 Overview

7.9.2 Recombinant Hormones: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.9.2.1 Recombinant Human Growth Hormones

7.9.2.1.1 Overview

7.9.2.1.2 Recombinant Human Growth Hormones: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.9.2.2 Recombinant Insulin

7.9.2.2.1 Overview

7.9.2.2.2 Recombinant Insulin: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.9.2.3 Other Recombinant Hormones

7.9.2.3.1 Overview

7.9.2.3.2 Other Recombinant Hormones: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.10 Recombinant Enzymes

7.10.1 Overview

7.10.2 Recombinant Enzymes: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.10.2.1 Enterokinase

7.10.2.1.1 Overview

7.10.2.1.2 Enterokinase: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.10.2.2 Cyclase

7.10.2.2.1 Overview

7.10.2.2.2 Cyclase: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.10.2.3 Caspase

7.10.2.3.1 Overview

7.10.2.3.2 Caspase: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.10.2.4 Cathepsin

7.10.2.4.1 Overview

7.10.2.4.2 Cathepsin: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.11 Cell and Gene Therapies

7.11.1 Overview

7.11.2 Cell and Gene Therapies: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.11.2.1 Allogenic Products

7.11.2.1.1 Overview

7.11.2.1.2 Allogenic Products: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.11.2.2 Autologous Products

7.11.2.2.1 Overview

7.11.2.2.2 Autologous Products: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.11.2.3 Acellular Products

7.11.2.3.1 Overview

7.11.2.3.2 Acellular Products: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.12 Cytokines/Interferon/Interleukins

7.12.1 Overview

7.12.2 Cytokines/Interferon/Interleukins: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

7.13 Others (mRNA Based Therapeutics, etc.)

7.13.1 Overview

7.13.2 Others (mRNA Based Therapeutics, etc.): Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8. Europe Biopharmaceuticals Market Analysis and Forecasts to 2028 – by Application

8.1 Overview

8.2 Europe Biopharmaceuticals Market, by Application 2021 & 2028 (%)

8.3 Oncology

8.3.1 Overview

8.3.2 Oncology: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Inflammatory and Infectious Diseases

8.4.1 Overview

8.4.2 Inflammatory and Infectious Diseases: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.5 Autoimmune Disorders

8.5.1 Overview

8.5.2 Autoimmune Disorders: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.6 Metabolic Disorders

8.6.1 Overview

8.6.2 Metabolic Disorders: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.7 Hormonal Disorders and Growth Failure

8.7.1 Overview

8.7.2 Hormonal Disorders and Growth Failure: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.8 Cardiovascular Diseases

8.8.1 Overview

8.8.2 Cardiovascular Diseases: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.9 Neurological Diseases

8.9.1 Overview

8.9.2 Neurological Diseases: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

8.10 Other Therapeutic Applications

8.10.1 Overview

8.10.2 Other Therapeutic Applications: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 – Country Analysis

9.1 Overview

9.1.1 Europe: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)

9.1.1.1 United Kingdom: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9.1.1.1.1 United Kingdom: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)

9.1.1.1.1.1 United Kingdom: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)

9.1.1.1.1.2 United Kingdom: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)

9.1.1.1.1.3 United Kingdom: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)

9.1.1.1.1.4 United Kingdom: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)

9.1.1.1.1.5 United Kingdom: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)

9.1.1.1.1.6 United Kingdom: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)

9.1.1.1.1.7 United Kingdom: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)

9.1.1.1.1.8 United Kingdom: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)

9.1.1.1.2 United Kingdom: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)

9.1.1.2 Germany: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9.1.1.2.1 Germany: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)

9.1.1.2.1.1 Germany: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)

9.1.1.2.1.2 Germany: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)

9.1.1.2.1.3 Germany: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)

9.1.1.2.1.4 Germany: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)

9.1.1.2.1.5 Germany: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)

9.1.1.2.1.6 Germany: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)

9.1.1.2.1.7 Germany: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)

9.1.1.2.1.8 Germany: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)

9.1.1.2.2 Germany: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)

9.1.1.3 France: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9.1.1.3.1 France: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)

9.1.1.3.1.1 France: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)

9.1.1.3.1.2 France: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)

9.1.1.3.1.3 France: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)

9.1.1.3.1.4 France: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)

9.1.1.3.1.5 France: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)

9.1.1.3.1.6 France: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)

9.1.1.3.1.7 France: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)

9.1.1.3.1.8 France: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)

9.1.1.3.2 France: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)

9.1.1.4 Italy: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9.1.1.4.1 Italy: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)

9.1.1.4.1.1 Italy: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)

9.1.1.4.1.2 Italy: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)

9.1.1.4.1.3 Italy: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)

9.1.1.4.1.4 Italy: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)

9.1.1.4.1.5 Italy: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)

9.1.1.4.1.6 Italy: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)

9.1.1.4.1.7 Italy: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)

9.1.1.4.1.8 Italy: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)

9.1.1.4.2 Italy: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)

9.1.1.5 Spain: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9.1.1.5.1 Spain: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)

9.1.1.5.1.1 Spain: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)

9.1.1.5.1.2 Spain: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)

9.1.1.5.1.3 Spain: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)

9.1.1.5.1.4 Spain: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)

9.1.1.5.1.5 Spain: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)

9.1.1.5.1.6 Spain: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)

9.1.1.5.1.7 Spain: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)

9.1.1.5.1.8 Spain: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)

9.1.1.5.2 Spain: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)

9.1.1.6 Rest of Europe: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

9.1.1.6.1 Rest of Europe: Biopharmaceuticals Market, by Product Type, 2019–2028 (US$ Million)

9.1.1.6.1.1 Rest of Europe: Biopharmaceuticals Market, by Recombinant Vaccines, 2019–2028 (US$ Million)

9.1.1.6.1.2 Rest of Europe: Biopharmaceuticals Market, by Conventional Vaccines, 2019–2028 (US$ Million)

9.1.1.6.1.3 Rest of Europe: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019–2028 (US$ Million)

9.1.1.6.1.4 Rest of Europe: Biopharmaceuticals Market, by Purified Proteins, 2019–2028 (US$ Million)

9.1.1.6.1.5 Rest of Europe: Biopharmaceuticals Market, by Recombinant Proteins, 2019–2028 (US$ Million)

9.1.1.6.1.6 Rest of Europe: Biopharmaceuticals Market, by Recombinant Hormones, 2019–2028 (US$ Million)

9.1.1.6.1.7 Rest of Europe: Biopharmaceuticals Market, by Recombinant Enzymes, 2019–2028 (US$ Million)

9.1.1.6.1.8 Rest of Europe: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019–2028 (US$ Million)

9.1.1.6.2 Rest of Europe: Biopharmaceuticals Market, by Application, 2019–2028 (US$ Million)

10. Europe Biopharmaceuticals Market – Industry Landscape

10.1 Overview

10.2 Organic Growth Strategies

10.2.1 Overview

10.3 Inorganic Growth Strategies

10.3.1 Overview

11. Company Profiles

11.1 Amgen Inc

11.1.1 Key Facts

11.1.2 Business Description

11.1.3 Products and Services

11.1.4 Financial Overview

11.1.5 SWOT Analysis

11.1.6 Key Developments

11.2 AbbVie Inc

11.2.1 Key Facts

11.2.2 Business Description

11.2.3 Products and Services

11.2.4 Financial Overview

11.2.5 SWOT Analysis

11.2.6 Key Developments

11.3 Eli Lilly and Co

11.3.1 Key Facts

11.3.2 Business Description

11.3.3 Products and Services

11.3.4 Financial Overview

11.3.5 SWOT Analysis

11.3.6 Key Developments

11.4 Bristol-Myers Squibb Co

11.4.1 Key Facts

11.4.2 Business Description

11.4.3 Products and Services

11.4.4 Financial Overview

11.4.5 SWOT Analysis

11.4.6 Key Developments

11.5 Johnson & Johnson

11.5.1 Key Facts

11.5.2 Business Description

11.5.3 Products and Services

11.5.4 Financial Overview

11.5.5 SWOT Analysis

11.5.6 Key Developments

11.6 Boehringer Ingelheim International GmbH

11.6.1 Key Facts

11.6.2 Business Description

11.6.3 Products and Services

11.6.4 Financial Overview

11.6.5 SWOT Analysis

11.6.6 Key Developments

11.7 Thermo Fisher Scientific Inc

11.7.1 Key Facts

11.7.2 Business Description

11.7.3 Products and Services

11.7.4 Financial Overview

11.7.5 SWOT Analysis

11.7.6 Key Developments

11.8 AGC Biologics AS

11.8.1 Key Facts

11.8.2 Business Description

11.8.3 Products and Services

11.8.4 Financial Overview

11.8.5 SWOT Analysis

11.8.6 Key Developments

11.9 Lonza Group AG

11.9.1 Key Facts

11.9.2 Business Description

11.9.3 Products and Services

11.9.4 Financial Overview

11.9.5 SWOT Analysis

11.9.6 Key Developments

11.10 WuXi Biologics Inc

11.10.1 Key Facts

11.10.2 Business Description

11.10.3 Products and Services

11.10.4 Financial Overview

11.10.5 SWOT Analysis

11.10.6 Key Developments

12. Appendix

12.1 About The Insight Partners

12.2 Glossary of Terms

LIST OF TABLES

Table 1. Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Table 2. United Kingdom Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)

Table 3. United Kingdom Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)

Table 4. United Kingdom Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)

Table 5. United Kingdom Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)

Table 6. United Kingdom Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)

Table 7. United Kingdom Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)

Table 8. United Kingdom Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)

Table 9. United Kingdom Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)

Table 10. United Kingdom Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)

Table 11. United Kingdom Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 12. Germany Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)

Table 13. Germany Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)

Table 14. Germany Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)

Table 15. Germany Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)

Table 16. Germany Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)

Table 17. Germany Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)

Table 18. Germany Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)

Table 19. Germany Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)

Table 20. Germany Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)

Table 21. Germany Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 22. France Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)

Table 23. France Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)

Table 24. France Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)

Table 25. France Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)

Table 26. France Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)

Table 27. France Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)

Table 28. France Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)

Table 29. France Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)

Table 30. France Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)

Table 31. France Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 32. Italy Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)

Table 33. Italy Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)

Table 34. Italy Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)

Table 35. Italy Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)

Table 36. Italy Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)

Table 37. Italy Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)

Table 38. Italy Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)

Table 39. Italy Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)

Table 40. Italy Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)

Table 41. Italy Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 42. Spain Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)

Table 43. Spain Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)

Table 44. Spain Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)

Table 45. Spain Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)

Table 46. Spain Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)

Table 47. Spain Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)

Table 48. Spain Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)

Table 49. Spain Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)

Table 50. Spain Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)

Table 51. Spain Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 52. Rest of Europe Biopharmaceuticals Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)

Table 53. Rest of Europe Biopharmaceuticals Market, by Recombinant Vaccines – Revenue and Forecast to 2028 (US$ Million)

Table 54. Rest of Europe Biopharmaceuticals Market, by Conventional Vaccines – Revenue and Forecast to 2028 (US$ Million)

Table 55. Rest of Europe Biopharmaceuticals Market, by Recombinant Growth Factors – Revenue and Forecast to 2028 (US$ Million)

Table 56. Rest of Europe Biopharmaceuticals Market, by Purified Proteins – Revenue and Forecast to 2028 (US$ Million)

Table 57. Rest of Europe Biopharmaceuticals Market, by Recombinant Proteins – Revenue and Forecast to 2028 (US$ Million)

Table 58. Rest of Europe Biopharmaceuticals Market, by Recombinant Hormones – Revenue and Forecast to 2028 (US$ Million)

Table 59. Rest of Europe Biopharmaceuticals Market, by Recombinant Enzymes – Revenue and Forecast to 2028 (US$ Million)

Table 60. Rest of Europe Biopharmaceuticals Market, by Cell & Gene Therapies – Revenue and Forecast to 2028 (US$ Million)

Table 61. Rest of Europe Biopharmaceuticals Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 62. Recent Organic Growth Strategies in Biopharmaceuticals Market

Table 63. Recent Inorganic Growth Strategies in the Europe biopharmaceuticals market

Table 64. Glossary of Terms

LIST OF FIGURES

Figure 1. Europe Biopharmaceuticals Market Segmentation

Figure 2. Europe Biopharmaceuticals Market, by Country

Figure 3. Europe Biopharmaceuticals Market Overview

Figure 4. Monoclonal Antibodies Segment Held Largest Share of Product Type Segment in Europe Biopharmaceuticals Market

Figure 5. UK Expected to Show Remarkable Growth During Forecast Period

Figure 6. Europe: PEST Analysis

Figure 7. Experts’ Opinion

Figure 8. Europe Biopharmaceuticals Market: Impact Analysis of Drivers and Restraints

Figure 9. Europe Biopharmaceuticals Market – Revenue Forecast and Analysis – 2020–2028

Figure 10. Europe Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)

Figure 11. Monoclonal Antibodies: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12. Recombinant Vaccines: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13. Cancer Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14. Malaria Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15. Ebola Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16. Hepatitis-B Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17. Tetanus Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18. Diphtheria Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 19. Cholera Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20. Others: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21. Conventional Vaccines: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22. Polio Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23. Pox Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24. Other Conventional Vaccine: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25. Recombinant Growth Factors: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26. Erythropoietin: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27. Granulocyte Colony Stimulating Factor: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 28. Purified Proteins: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29. Leukemia Inhibitory Factor (LIF): Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30. P53 Protein: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31. P38 Protein: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32. Other Purified Proteins: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 33. Recombinant Proteins: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 34. Serum Albumin: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 35. Amyloid Protein: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36. Defensin: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37. Transferrin: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 38. Recombinant Hormones: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 39. Recombinant Human Growth Hormones: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 40. Recombinant Insulin: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 41. Other Recombinant Hormones: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 42. Recombinant Enzymes: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 43. Enterokinase: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 44. Cyclase: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 45. Caspase: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 46. Cathepsin: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 47. Cell and Gene Therapies: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 48. Allogenic Products: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 49. Autologous Products: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 50. Acellular Products: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 51. Cytokines/Interferon/Interleukins: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 52. Others (mRNA Based Therapeutics, etc.): Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 53. Europe Biopharmaceuticals Market, by Application 2021 & 2028 (%)

Figure 54. Oncology: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 55. Inflammatory and Infectious Diseases: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 56. Autoimmune Disorders: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 57. Metabolic Disorders: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 58. Hormonal Disorders and Growth Failure: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 59. Cardiovascular Diseases: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 60. Neurological Diseases: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 61. Other Therapeutic Applications: Europe Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 62. Europe: Biopharmaceuticals Market, by Key Country – Revenue (2021) (US$ Million)

Figure 63. Europe: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)

Figure 64. United Kingdom: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 65. Germany: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 66. France: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 67. Italy: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 68. Spain: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)

Figure 69. Rest of Europe: Biopharmaceuticals Market – Revenue and Forecast to 2028 (US$ Million)